Award
National Cancer Institute 11366494
Protein O' Mannosylation as a therapeutic vulnerability in KIAA1549-BRAF-driven pediatric low-grade glioma
Recipient
National Cancer Institute (NCI)
Award Amount
$721,653.00
Ceiling
$721,653.00
Awarded
June 09, 2026
Identifier
11366494
This NIH-funded project led by Drs. Beroukhim and Bandopadhayay investigates the role of protein O' mannosylation in pediatric low-grade glioma driven by KIAA1549-BRAF fusion. The research aims to explore therapeutic vulnerabilities and toxicity of POMT suppression, contributing to targeted therapy development for childhood brain tumors.
Description
The project involves dissection of mechanisms related to POMT complex and KIAA1549-BRAF fusion in pediatric glioma. It aims to validate therapeutic potential and evaluate toxicity of POMT suppression in pediatric models. The project focuses on glycosylation of KIAA1549 by POMT as a step in oncogenesis and involves extensive molecular and animal studies. It addresses pediatric low-grade glioma, a common childhood brain tumor, emphasizing the development of targeted therapies and understanding of toxicity in young models.